1-4 of 4
B. Wassmann
Close
Sort by
Journal Articles

Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Heike Pfeifer, MD, B. Wassmann, MD, Wolfgang A. Bethge, MD, Jolanta Dengler, MD, Martin Bornhäuser, MD, Michael Stadler, MD, Dietrich Beelen, Andreas Günther, MD, Vladan Vucinic, Thomas Burmeister, MD, Matthias Stelljes, Rainer Schwerdtfeger, Kerstin Schaefer-Eckhart, Peter Bader, Hermann Kreyenberg, Peter Schuld, PhD, Hubert Serve, MD, Dieter Hoelzer, MD, Nicola Goekbuget, MD, Oliver G. Ottmann, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 247.
https://doi.org/10.1182/blood.V118.21.247.247
Published: 2011
Journal Articles

Long-Term Outcome of 335 Adult Patients Receiving Different Schedules of Imatinib and Chemotherapy as Front-Line Treatment for Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Heike Pfeifer, MD, Nicola Goekbuget, MD, Christian Völp, MD, Andreas Hüttmann, MD, Michael Lübbert, MD, Reingard Stuhlmann, MD, Julanta Dengler, MD, Karl-Anton Kreuzer, MD, Joachim Beck, MD, Matthias Stelljes, MD, Mathias Schmid, MD, B. Wassmann, MD, Lothar Leimer, MD, Karsten Spiekermann, MD, Theis H Terwey, MD, K. Schäfer-Eckart, MD, D. Ditz, MD, H. Lindemann, MD, A. Morgner, MD, Markus Schaich, MD, Thomas Burmeister, MD, A. Binckebanck, Dieter Hoelzer, MD, Oliver G. Ottmann, MD
Journal: Blood
Blood (2010) 116 (21): 173.
https://doi.org/10.1182/blood.V116.21.173.173
Published: 2010
Journal Articles

A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).

Francis Giles, MD, H. Kantarjian, MD, B. Wassmann, J. Cortes, MD, S. O’Brien, MD, C. Tanaka, P. Rae, W. Mietlowski, A. Romano, L. Alland, M. Dugan, M. Albitar, MD, O. Ottmann
Journal: Blood
Blood (2004) 104 (11): 22.
https://doi.org/10.1182/blood.V104.11.22.22
Published: 2004
Journal Articles

Durable Molecular Remissions in Patients with Relapsed CML Post Allogeneic Stem Cell Transplantation upon Treatment with Imatinib-Mesylate (Glivec®, STI-571). Follow-Up Results of a Phase II Open-Label Study.

G. Hess, MD, D. Bunjes, MD, W. Siegert, MD, R. Schwerdtfeger, MD, G. Ledderose, MD, B. Waßmann, MD, G. Kobbe, MD, M. Bornhäuser, MD, A. Hochhaus, MD, A. J. Ullmann, MD, T. Kindler, MD, H. Geschaidmeier, PhD, C. Huber11, MD, T. Fischer12, MD
Journal: Blood
Blood (2004) 104 (11): 1004.
https://doi.org/10.1182/blood.V104.11.1004.1004
Published: 2004